Franklin Matthew C, Carey Kendall D, Vajdos Felix F, Leahy Daniel J, de Vos Abraham M, Sliwkowski Mark X
Department of Protein Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94114 USA.
Cancer Cell. 2004 Apr;5(4):317-28. doi: 10.1016/s1535-6108(04)00083-2.
We have determined the 3.2 A X-ray crystal structure of the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2 or HER2) in a complex with the antigen binding fragment of pertuzumab, an anti-ErbB2 monoclonal antibody also known as 2C4 or Omnitarg. Pertuzumab binds to ErbB2 near the center of domain II, sterically blocking a binding pocket necessary for receptor dimerization and signaling. The ErbB2-pertuzumab structure, combined with earlier mutagenesis data, defines the pertuzumab residues essential for ErbB2 interaction. To analyze the ErbB2 side of the interface, we have mutated a number of residues contacting pertuzumab and examined the effects of these mutations on pertuzumab binding and ErbB2-ErbB3 heterodimerization. We have also shown that conserved residues previously shown to be necessary for EGF receptor homodimerization may be dispensible for ErbB2-ErbB3 heterodimerization.
我们已经确定了人表皮生长因子受体2(ErbB2或HER2)细胞外结构域与帕妥珠单抗抗原结合片段形成复合物的3.2埃X射线晶体结构,帕妥珠单抗是一种抗ErbB2单克隆抗体,也称为2C4或Omnitarg。帕妥珠单抗在结构域II中心附近与ErbB2结合,在空间上阻断受体二聚化和信号传导所需的结合口袋。ErbB2-帕妥珠单抗结构与早期的诱变数据相结合,确定了帕妥珠单抗与ErbB2相互作用所必需的残基。为了分析界面处ErbB2一侧的情况,我们对一些与帕妥珠单抗接触的残基进行了突变,并研究了这些突变对帕妥珠单抗结合以及ErbB2-ErbB3异二聚化的影响。我们还表明,先前显示对表皮生长因子受体同二聚化必需的保守残基对于ErbB2-ErbB3异二聚化可能是不必要的。